John L. Marshall, MD, discusses the impact of the SUNLIGHT trial in patients with refractory metastatic colorectal cancer.

In addition, transient VEGF expression after adenoviral gene transfer in the heart only induces a short-lived angiogenic response 12. Inhibition of VEGF during active angiogenesis halts vascular ...

The quest for VEGF and other factors that promote tumour angiogenesis was initiated many decades ago, and a long and complicated path has led to the development of inhibitors of these molecules as ...

Recent discoveries in ophthalmology and vascular biology, however, suggest that combined inhibition of VEGF and platelet-derived growth factor (PDGF) may be more beneficial than inhibition of VEGF ...

Abexinostat, an HDAC2 inhibitor, restores chromatin AC, thereby inhibiting HIF1-α and reducing VEGF expression. This results in diminished vascular promotion and improved survival outcomes, ...

Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung cancer (NSCLC) by 9 months compared ...

Furthermore, existing marketed anti-VEGF agents are being studied in combination with novel PDGF inhibitors for dual therapy. Thus, it is important to consider the history of VEGF antagonists for ...

PD-1/PD-L1 inhibitor and CTLA-4 inhibitor (IO/IO), and a combination of PD-1/PD-L1 inhibitor with a VEGF-receptor inhibitor (IO/VEGF). In the IO/IO cohort, patients with exceptional responses had ...